Patents by Inventor Chenguang Zhao
Chenguang Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240111062Abstract: Disclosed is a polarization fusion orientation method for an occluded environment, which comprises: acquiring a sky polarization image through a polarization camera first, then taking a heading angle output by an E-vector polarization orientation method as a state quantity, taking a heading angle output by a symmetry axis polarization orientation method as an observed quantity, realizing heading angle fusion through a multi-frequency variational Bayesian strong tracking cubature Kalman filter (MF-VBSTCKF), and respectively selecting different methods for a sampling position and a sampling interval period to update an optimal heading angle. The method solves the problem that high-precision and high-robustness heading angle measurement of polarized light cannot be realized in the occluded environment, can improve the precision and robustness of a polarized light orientation method in the occluded environment, and ensures high-frequency output of the heading angle at the same time.Type: ApplicationFiled: June 12, 2023Publication date: April 4, 2024Inventors: Chong SHEN, Huijun ZHAO, Jun LIU, Jun TANG, Huiliang CAO, Chenguang WANG
-
Publication number: 20230263822Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.Type: ApplicationFiled: January 5, 2023Publication date: August 24, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Chenguang Zhao, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Andrew M. Siwkowski
-
Patent number: 11574728Abstract: The present disclosure relates to a medical imaging method for enabling magnetic resonance imaging of a subject (318) using a set of imaging parameters of imaging protocols, the method comprising: receiving information related to the subject; using a predefined machine learning model for suggesting at least one imaging protocol for the received information, wherein the imaging protocol comprises at least part of the set of imaging parameters and associated values; providing the imaging protocol.Type: GrantFiled: June 19, 2019Date of Patent: February 7, 2023Assignee: Koninklijke Philips N.V.Inventors: Thomas Erik Amthor, Liqin Wang, Chenguang Zhao, Joachim Dieter Schmidt, Jorn Borgert, Yajing Zhang, Ingmar Graesslin, Tanja Nordhoff
-
Publication number: 20230002771Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of FXII RNA in a cell or subject, and in certain instances reducing the amount of FXII protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to prevent, treat, or ameliorate at least one symptom of a thromboembolic condition. Such thromboembolic conditions include deep vein thrombosis, venous or arterial thrombosis, pulmonary embolism, myocardial infarction, and stroke. Such symptoms include pain, shortness of breath, heart burn, cold sweat, fatigue, lightheadedness, dizziness, swelling, cramping, and death. Such compounds, methods, and pharmaceutical compositions are useful to prevent, treat, or ameliorate at least one symptom of hereditary angioedema.Type: ApplicationFiled: December 17, 2021Publication date: January 5, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Huynh-Hoa Bui, Chenguang Zhao, Brett P. Monia, Jeffrey R. Crosby
-
Patent number: 11376273Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.Type: GrantFiled: July 29, 2020Date of Patent: July 5, 2022Assignee: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Chenguang Zhao, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Andrew M. Siwkowski
-
Publication number: 20210169921Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.Type: ApplicationFiled: July 29, 2020Publication date: June 10, 2021Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Chenguang Zhao, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Andrew M. Siwkowski
-
Publication number: 20210118554Abstract: The present disclosure relates to a medical imaging method for enabling magnetic resonance imaging of a subject (318) using a set of imaging parameters of imaging protocols, the method comprising: receiving information related to the subject; using a predefined machine learning model for suggesting at least one imaging protocol for the received information, wherein the imaging protocol comprises at least part of the set of imaging parameters and associated values; providing the imaging protocol.Type: ApplicationFiled: June 19, 2019Publication date: April 22, 2021Inventors: THOMAS ERIK AMTHOR, LIQIN WANG, CHENGUANG ZHAO, JOACHIM DIETER SCHMIDT, JORN BORGERT, YAJING ZHANG, INGMAR GRAESSLIN, TANJA NORDHOFF
-
Publication number: 20200000839Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.Type: ApplicationFiled: February 12, 2019Publication date: January 2, 2020Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Chenguang Zhao, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Andrew M. Siwkowski
-
Patent number: 10429471Abstract: The invention provides a device for producing a magnetic resonance image.Type: GrantFiled: June 7, 2016Date of Patent: October 1, 2019Assignee: Koninklijke Philips N.V.Inventors: Chenguang Zhao, Feng Huang, Ming Yang
-
Publication number: 20180149720Abstract: The invention provides a device for producing a magnetic resonance image.Type: ApplicationFiled: June 7, 2016Publication date: May 31, 2018Inventors: CHENGUANG ZHAO, FENG HUANG, MING YANG
-
Publication number: 20170035798Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.Type: ApplicationFiled: March 21, 2016Publication date: February 9, 2017Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Chenguang Zhao, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Andrew M. Siwkowski
-
Patent number: 9029337Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 7 and treating or preventing thromboembolic complications, hyperproliferative disorders, or inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 7 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, cancer, rheumatoid arthritis, and fibrosis.Type: GrantFiled: November 5, 2008Date of Patent: May 12, 2015Assignee: Isis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Chenguang Zhao
-
Patent number: 8735370Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.Type: GrantFiled: October 8, 2012Date of Patent: May 27, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Chenguang Zhao, Jeffrey R. Crosby, Andrew M. Siwkowski
-
Publication number: 20130274308Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.Type: ApplicationFiled: October 8, 2012Publication date: October 17, 2013Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Chenguang Zhao, Jeffrey R. Crosby, Andrew M. Siwkowski
-
Patent number: 8334372Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.Type: GrantFiled: October 15, 2009Date of Patent: December 18, 2012Assignee: Isis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Chenguang Zhao, Jeffrey R. Crosby, Andrew M. Siwkowski
-
Publication number: 20120214862Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 7 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 7 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 7 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.Type: ApplicationFiled: July 15, 2010Publication date: August 23, 2012Applicant: ISIS Pharmaceuticals, Inc.Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Chenguang Zhao
-
Publication number: 20110059895Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 9 and increasing clotting time in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 9 include thrombosis, embolism, thromoboembolism such as deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke.Type: ApplicationFiled: November 5, 2008Publication date: March 10, 2011Applicant: Isis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Chenguang Zhao
-
Publication number: 20100298417Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 7 and treating or preventing thromboembolic complications, hyperproliferative disorders, or inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 7 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, cancer, rheumatoid arthritis, and fibrosis.Type: ApplicationFiled: November 5, 2008Publication date: November 25, 2010Applicant: Isis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Chenguang Zhao
-
Publication number: 20100137414Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.Type: ApplicationFiled: October 15, 2009Publication date: June 3, 2010Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Chenguang Zhao, Jeffrey R. Crosby, Andrew M. Siwkowski